Supernus reports positive topline results from 2 phase III studies of SPN812 in children with ADHD

Supernus reports positive topline results from 2 phase III studies of SPN─812 in children with ADHD

16:01 EST 8 Dec 2018 | PharmaBiz

Supernus Pharmaceuticals, Inc, a pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, announced positive topline results from each of two pivotal phase III studies

More From BioPortfolio on "Supernus reports positive topline results from 2 phase III studies of SPN─812 in children with ADHD"